What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles
Authors
Keywords
Antibiotics, Development, Pipeline, Resistance, Pharmacodynamics
Journal
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
Volume 44, Issue 2, Pages 113-132
Publisher
Springer Nature
Online
2017-02-04
DOI
10.1007/s10928-017-9506-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases
- (2016) Tsukasa Ito-Horiyama et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Association of Novel Nonsynonymous Single Nucleotide Polymorphisms inampDwith Cephalosporin Resistance and Phylogenetic Variations inampC,ampR,ompF, andompCin Enterobacter cloacae Isolates That Are Highly Resistant to Carbapenems
- (2016) Baharak Babouee Flury et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The role of solithromycin in the management of bacterial community-acquired pneumonia
- (2016) Françoise Van Bambeke et al. Expert Review of Anti-Infective Therapy
- In vitropharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms
- (2016) Sherwin K. B. Sy et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study
- (2016) Yi-Yun Liu et al. LANCET INFECTIOUS DISEASES
- Tetracycline Antibiotics and Resistance
- (2016) Trudy H. Grossman Cold Spring Harbor Perspectives in Medicine
- Mechanisms of drug resistance: quinolone resistance
- (2015) David C. Hooper et al. Annals of the New York Academy of Sciences
- Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model
- (2015) Wonhee So et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy
- (2015) Aryun Kim et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy and Safety of AFN-1252, the First Staphylococcus-Specific Antibacterial Agent, in the Treatment of Acute Bacterial Skin and Skin Structure Infections, Including Those in Patients with Significant Comorbidities
- (2015) B. Hafkin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins
- (2015) M. Berrazeg et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City
- (2015) Amabel Lapuebla et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroAntibacterial Activity of the Ceftazidime-Avibactam Combination against Enterobacteriaceae, Including Strains with Well-Characterized β-Lactamases
- (2015) Premavathy Levasseur et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-Avibactam Activity Tested against Enterobacteriaceae Isolates from U.S. Hospitals (2011 to 2013) and Characterization of β-Lactamase-Producing Strains
- (2015) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum β-Lactamases, and Porin Mutations on theIn VitroActivity of Ceftazidime-Avibactam against Carbapenem-Resistant K. pneumoniae
- (2015) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City
- (2015) Amabel Lapuebla et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa
- (2015) Krystyna M. Kazmierczak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroAntimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains
- (2015) Naoki Kohira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSelection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase
- (2015) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases
- (2015) Krisztina M. Papp-Wallace et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Finafloxacin: First Global Approval
- (2015) Kate McKeage DRUGS
- Delafloxacin for the treatment of respiratory and skin infections
- (2015) Matteo Bassetti et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates
- (2015) Raymond Testa et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens
- (2015) Karen Bush INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitroantimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria
- (2015) Akinobu Ito et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases
- (2015) David M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam
- (2015) Renu Singh et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public–private partnerships for the development of new strategies to tackle antibiotic resistance
- (2015) T. Kostyanev et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Characterization ofEscherichia coliNDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3
- (2015) Richard A. Alm et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam ‘enhancer’
- (2015) Akihiro Morinaka et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Molecular Basis of Filtering Carbapenems by Porins from β-Lactam-resistant Clinical Strains ofEscherichia coli
- (2015) Harsha Bajaj et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of Efficacious Pseudomonas aeruginosa-Targeted Siderophore-Conjugated Monocarbams by Application of a Semi-mechanistic Pharmacokinetic/Pharmacodynamic Model
- (2015) Kerry E. Murphy-Benenato et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases
- (2015) Scott J. Hecker et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914)
- (2015) Gregory S. Basarab et al. JOURNAL OF MEDICINAL CHEMISTRY
- The metabolism and disposition of GSK2140944 in healthy human subjects
- (2015) Kitaw Negash et al. XENOBIOTICA
- Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases
- (2015) Gregory S. Basarab et al. Scientific Reports
- Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial
- (2015) Chin Kook Rhee et al. International Journal of Chronic Obstructive Pulmonary Disease
- Mutation-Driven β-Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates from U.S. Hospitals
- (2014) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Exposure to Ceftobiprole Is Associated with Microbiological Eradication and Clinical Cure in Patients with Nosocomial Pneumonia
- (2014) A. E. Muller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC
- (2014) Gabriel Cabot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSusceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations
- (2014) Henry Li et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics of Imipenem in Combination with β-Lactamase Inhibitor MK7655 in a Murine Thigh Model
- (2014) Eleftheria Mavridou et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Carbapenem-Resistant Klebsiella pneumoniae Strains Exhibit Diversity in Aminoglycoside-Modifying Enzymes, Which Exert Differing Effects on Plazomicin and Other Agents
- (2014) Reem Almaghrabi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparative Mechanistic Studies of Brilacidin, Daptomycin, and the Antimicrobial Peptide LL16
- (2014) Bruk Mensa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa
- (2014) Marisa L. Winkler et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Challenge of Antimicrobial Resistance: New Regulatory Tools to Support Product Development
- (2014) J F Tomayko et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising?
- (2014) Malcolm GP Page et al. CURRENT OPINION IN PHARMACOLOGY
- Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients
- (2014) Jan J. De Waele et al. INTENSIVE CARE MEDICINE
- Determination of Disk Diffusion and MIC Quality Control Guidelines for GSK2140944, a Novel Bacterial Type II Topoisomerase Inhibitor Antimicrobial Agent
- (2014) J. E. Ross et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
- (2014) Jason A Roberts et al. LANCET INFECTIOUS DISEASES
- ND4BB: addressing the antimicrobial resistance crisis
- (2014) John H. Rex NATURE REVIEWS MICROBIOLOGY
- Involvement of Fe Uptake Systems and AmpC β-Lactamase in Susceptibility to the Siderophore Monosulfactam BAL30072 in Pseudomonas aeruginosa
- (2013) Christian van Delden et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Adaptation-Based Resistance to Siderophore-Conjugated Antibacterial Agents by Pseudomonas aeruginosa
- (2013) Andrew P. Tomaras et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World
- (2013) Sarah M. Drawz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in anIn VitroInfection Model
- (2013) Brian VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial Activity of the Pleuromutilin Antibiotic BC-3781 against Bacterial Pathogens Isolated in the SENTRY Antimicrobial Surveillance Program in 2010
- (2013) Susanne Paukner et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens
- (2013) J. A. Sutcliffe et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroandIn VivoAntibacterial Activities of Omadacycline, a Novel Aminomethylcycline
- (2013) A. B. Macone et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Is the GAIN Act a turning point in new antibiotic discovery?
- (2013) Eric D. Brown CANADIAN JOURNAL OF MICROBIOLOGY
- 10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America
- (2013) H. W. Boucher et al. CLINICAL INFECTIOUS DISEASES
- Investigational Antimicrobial Agents of 2013
- (2013) M. J. Pucci et al. CLINICAL MICROBIOLOGY REVIEWS
- Efficient Antibacterial Agents: A Review of the Synthesis, Biological Evaluation and Mechanism of Pleuromutilin Derivatives
- (2013) Ruofeng Shang et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens
- (2013) Michael Hornsey et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Antibiotics in the clinical pipeline in 2013
- (2013) Mark S Butler et al. JOURNAL OF ANTIBIOTICS
- Activity of BAL30072 alone or combined with -lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters
- (2013) S. Mushtaq et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
- (2013) David E. Ehmann et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Carbapenemases: Partners in crime
- (2013) Karen Bush Journal of Global Antimicrobial Resistance
- Clinically Relevant Gram-Negative Resistance Mechanisms Have No Effect on the Efficacy of MC-1, a Novel Siderophore-Conjugated Monocarbam
- (2012) Craig J. McPherson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase Inhibitors
- (2012) Pratik Bhagunde et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β-Lactamases and Methicillin-Resistant Staphylococcus aureus Carrying Various Staphylococcal Cassette ChromosomemecTypes
- (2012) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial Activity of the Investigational Pleuromutilin Compound BC-3781 Tested against Gram-Positive Organisms Commonly Associated with Acute Bacterial Skin and Skin Structure Infections
- (2012) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VivoActivities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice
- (2012) W. A. Craig et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Inhibition of Lipopolysaccharide Transport to the Outer Membrane in Pseudomonas aeruginosa by Peptidomimetic Antibiotics
- (2012) Martina Werneburg et al. CHEMBIOCHEM
- Safety and Clinical Pharmacokinetics of Nemonoxacin, a Novel Non-Fluorinated Quinolone, in Healthy Chinese Volunteers Following Single and Multiple Oral Doses
- (2012) Beining Guo et al. CLINICAL DRUG INVESTIGATION
- Accelerating resistance, inadequate antibacterial drug pipelines and international responses
- (2012) Ursula Theuretzbacher INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)
- (2012) H. S. Sader et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia
- (2012) A. E. Muller et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Avibactam is a covalent, reversible, non- -lactam -lactamase inhibitor
- (2012) D. E. Ehmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world
- (2011) Roger M. Echols Annals of the New York Academy of Sciences
- Antibiotics in development targeting protein synthesis
- (2011) Joyce A. Sutcliffe Annals of the New York Academy of Sciences
- Human Pharmacokinetics and Safety Profile of Finafloxacin, a New Fluoroquinolone Antibiotic, in Healthy Volunteers
- (2011) Heena Patel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antistaphylococcal Activity of TD-1792, a Multivalent Glycopeptide-Cephalosporin Antibiotic
- (2011) Johanne Blais et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes
- (2011) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSpectrum of Activity of Finafloxacin, a Novel, pH-Activated Fluoroquinolone, under Standard and Acidic Conditions
- (2011) Will Stubbings et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach
- (2011) J.W. Mouton et al. CLINICAL MICROBIOLOGY AND INFECTION
- In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14– and CTX-M-15–producing Escherichia coli and Klebsiella pneumoniae
- (2011) Emilia Titelman et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa
- (2010) B. Moya et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity against Multiresistant Gram-Negative Bacilli
- (2010) M. G. P. Page et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Synthesis and Spectrum of the Neoglycoside ACHN-490
- (2010) J. B. Aggen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates
- (2010) D. M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus -lactamase-producing Enterobacteriaceae
- (2010) D. M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009)
- (2010) David J. Farrell et al. JOURNAL OF INFECTION
- Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa
- (2010) S. Han et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
- (2008) Helen W. Boucher et al. CLINICAL INFECTIOUS DISEASES
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started